OR WAIT null SECS
Patricia Van Arnum was executive editor of Pharmaceutical Technology.
December 06, 2007
Bristol-Myers Squibb outlined a comprehensive review of its operations and a strategy to improve top-line growth, a plan that involves staff reductions and rationalization of its manufacturing plants.
December 05, 2007
The number of new molecular entities approved by the US Food and Drug Administration is down this year as the pharmaeutical industry continues to face an innovation drought.
Big Pharma's strategic push into biologics and continuing restructuring are among the highlights for 2007.
Chi-wan Chen, deputy director of the Office of New Drug Quality Assessment (ONDQA) at the US Food and Drug Administration's Center for Drug Evaluation and Research, shares insight from FDA's pilot program that was designed to allow pharmaceutical companies to submit CMC information demonstrating application of quality by design.
December 02, 2007
A surge in capacity in contract microbial and mammalian cell-culture is underway to meet rising production needs for biopharmaceuticals.
November 29, 2007
GlaxoSmithKline agreed to acquire Reliant Pharmaceuticals for $1.65 billion in cash.